Should I pick individual healthcare stocks?

Requires domain knowledge most retail investors don't have. In pharma, returns often hinge on binary clinical trial outcomes and patent cliffs. In medtech, the risk is more subtle—choosing a business that eventually behaves like a commodity.

Do sector ETFs solve that problem?

Partially. They eliminate the need to pick individual companies, but they don't eliminate concentration risk. As IHI demonstrates, sector ETFs can still be driven by a small number of dominant holdings.

Did any healthcare option outperform the overall market?

No. A plain S&P 500 index fund outperformed both IHI and IHE across every period measured, from 1 year through 15 years.

So why buy a healthcare ETF at all?

It should be an intentional portfolio decision—not a default choice. Consider a healthcare ETF only if you have a specific conviction that the sector will outperform, or if you want targeted healthcare exposure within a broader diversified portfolio.

Pharma vs. Medtech ETFs: What You're Actually Buying

2 days ago
4 min read

Article 5 of 5 in the Pharma vs. Medtech Series

The medtech ETF beat the pharma ETF over the last decade — not because medtech won, but because two stocks inside it did

Prepared by Richstorm.co

Key Takeaways

The S&P 500 beat both IHI and IHE at every single time horizon measured — 1, 3, 5, and 10 years — with no exception.
IHI (medtech) beat IHE (pharma) over 10 years — 12.58% vs. 4.18% annualized — despite medtech's structurally lower margins across the industry.
That result comes almost entirely from two holdings: Abbott and Intuitive Surgical are roughly a third of IHI's assets, and both are the moat exceptions this series has already identified.
Over 1, 3, and 5 years, pharma (IHE) has actually outperformed medtech (IHI) — the 10-year number is the outlier.
For most retail investors, a broad total market fund beat every option in this article's tables — a sector ETF is a concentrated bet on healthcare outperforming, holding far fewer companies than the S&P 500.

The Options

Five funds cover the ground between pure pharma and pure medtech exposure, and they differ a lot more than their category labels suggest.

Source: iShares, State Street (SPDR), and Vanguard fund fact sheets.

The Performance Numbers

Here's how each fund actually performed, checked against every time horizon that matters, not just whichever one tells the best story.

Table: IHI vs. IHE total returns across time horizons.

Source: financecharts.com; same snapshot date across IHI, IHE, and the S&P 500.

Notice the pattern: pharma wins every window except the 10-year one. That reversal is worth understanding before treating either number as "the" answer. But look at the benchmark column too — the S&P 500 beat both IHI and IHE at every single horizon measured, 1 through 15 years, with no exception.

Neither healthcare sub-sector actually won over any of these periods; the broad market did. And the IHI-vs-IHE gap itself is fragile: at 10 years medtech leads by 8.4 points, but stretch to 15 years and that gap shrinks to just 2.1 points — the "medtech wins long-term" story mostly depends on which decade you pick.

Why IHI Actually Won the 10-Year Number

IHI looks diversified on paper — 51 holdings. Look at where the actual weight sits, and a very different picture shows up.

Table: Just four holdings make up more than half of IHI.

Source: iShares IHI fund holdings disclosure.

Put side by side, the gap between the story this fund tells and what's actually driving its return is stark.

The clearest way to prove the concentration point is to compare the fund directly against the two stocks actually driving it.

Source: financecharts.com; same snapshot date as the fund-level figures above.

This is the concentration point made concrete. At every horizon, ISRG alone beats the IHI fund it's part of — 19.11% vs. 12.58% at 10 years, 17.12% vs. 12.90% at 15 years. The fund's other 49 holdings dilute the return of the one stock actually driving it. An investor who bought Intuitive Surgical directly, understanding why its moat was real, would have beaten the "diversified" medtech ETF built partly around owning it.

What This Means for an Actual Decision

None of the options above is universally right — it depends on what exposure you're actually trying to get.

Why Medtech Won This Decade — An Honest Accounting

Before accepting any explanation for the 10-year gap, here's what actually checks out against real data, and what each finding does or doesn't prove.

The honest answer is that this decade's result doesn't reduce to one clean, generalizable reason. Multiple real, separately-verified factors contributed — two exceptional individual companies, one large pharma holding's pandemic-driven decline, a concentration structure that wasn't actually more diluted for pharma than for medtech — but no single story explains the full gap, and none of them predicts what the next decade will look like. Markets don't always resolve into a tidy narrative, and forcing one here would be less honest than saying plainly: the mechanism is unclear.

The Bottom Line

Reduced to the questions that actually matter for a decision:

Should I pick individual healthcare stocks?
Requires domain knowledge most retail investors don't have. In pharma, returns often hinge on binary clinical trial outcomes and patent cliffs. In medtech, the risk is more subtle—choosing a business that eventually behaves like a commodity.
Do sector ETFs solve that problem?
Partially. They eliminate the need to pick individual companies, but they don't eliminate concentration risk. As IHI demonstrates, sector ETFs can still be driven by a small number of dominant holdings.
Did any healthcare option outperform the overall market?
No. A plain S&P 500 index fund outperformed both IHI and IHE across every period measured, from 1 year through 15 years.
So why buy a healthcare ETF at all?
It should be an intentional portfolio decision—not a default choice. Consider a healthcare ETF only if you have a specific conviction that the sector will outperform, or if you want targeted healthcare exposure within a broader diversified portfolio.